Daenen LG - Search Results

1

Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.

Mans DA, Vermaat JS, Weijts BG, van Rooijen E, van Reeuwijk J, Boldt K, Daenen LG, van der Groep P, Rowland BD, Jans JJ, Roepman R, Voest EE, van Diest PJ, Verhaar MC, de Bruin A, Giles RH. Mans DA, et al. Among authors: daenen lg. J Pathol. 2013 Sep;231(1):117-29. doi: 10.1002/path.4219. J Pathol. 2013. PMID: 23744542

2

Mobility of the von Hippel-Lindau tumour suppressor protein is regulated by kinesin-2.

Mans DA, Lolkema MP, van Beest M, Daenen LG, Voest EE, Giles RH. Mans DA, et al. Among authors: daenen lg. Exp Cell Res. 2008 Apr 1;314(6):1229-36. doi: 10.1016/j.yexcr.2007.12.020. Epub 2008 Jan 5. Exp Cell Res. 2008. PMID: 18261724

3

Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back.

Roodhart JM, Langenberg MH, Daenen LG, Voest EE. Roodhart JM, et al. Among authors: daenen lg. Biochim Biophys Acta. 2009 Aug;1796(1):41-9. doi: 10.1016/j.bbcan.2009.04.006. Epub 2009 May 4. Biochim Biophys Acta. 2009. PMID: 19409450 Review.

4

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.

Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, Kerbel RS. Daenen LG, et al. Mol Cancer Ther. 2009 Oct;8(10):2872-81. doi: 10.1158/1535-7163.MCT-09-0583. Mol Cancer Ther. 2009. PMID: 19825805 Free PMC article.

5

Vascular disrupting agents (VDAs) in anticancer therapy.

Daenen LG, Roodhart JM, Shaked Y, Voest EE. Daenen LG, et al. Curr Clin Pharmacol. 2010 Aug;5(3):178-85. doi: 10.2174/157488410791498815. Curr Clin Pharmacol. 2010. PMID: 20406172 Review.

6

Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.

Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PW, Medema RH, Martens AC, Brenkman AB, Voest EE. Roodhart JM, et al. Among authors: daenen lg. Cancer Cell. 2011 Sep 13;20(3):370-83. doi: 10.1016/j.ccr.2011.08.010. Cancer Cell. 2011. PMID: 21907927 Free article.

7

Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells.

Daenen LG, Roodhart JM, van Amersfoort M, Dehnad M, Roessingh W, Ulfman LH, Derksen PW, Voest EE. Daenen LG, et al. Cancer Res. 2011 Nov 15;71(22):6976-85. doi: 10.1158/0008-5472.CAN-11-0627. Epub 2011 Oct 5. Cancer Res. 2011. PMID: 21975929

8

The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression.

Houthuijzen JM, Daenen LG, Roodhart JM, Voest EE. Houthuijzen JM, et al. Among authors: daenen lg. Br J Cancer. 2012 Jun 5;106(12):1901-6. doi: 10.1038/bjc.2012.201. Epub 2012 May 17. Br J Cancer. 2012. PMID: 22596239 Free PMC article. Review.

9

Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.

Kroeze SG, Daenen LG, Nijkamp MW, Roodhart JM, de Gast GC, Bosch JL, Jans JJ. Kroeze SG, et al. Among authors: daenen lg. J Urol. 2012 Aug;188(2):607-14. doi: 10.1016/j.juro.2012.03.116. Epub 2012 Jun 15. J Urol. 2012. PMID: 22704448

10

Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies.

Daenen LG, Houthuijzen JM, Cirkel GA, Roodhart JM, Shaked Y, Voest EE. Daenen LG, et al. Oncogene. 2014 Mar 13;33(11):1341-7. doi: 10.1038/onc.2013.94. Epub 2013 Mar 25. Oncogene. 2014. PMID: 23524584 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page